Socioeconomic burden of amyotrophic lateral sclerosis, myasthenia gravis and facioscapulohumeral muscular dystrophy

Journal of Neurology

Volumn 257, Issue 1, 2010, Pages 15-23

  Schepelmann, Karsten ^a   Winter, Yaroslav ^a   Spottke, Annika E ^b   Claus, Detlef ^c   Grothe, Christoph ^b   Schröder, Rolf ^b   Heuss, Dieter ^d   Vielhaber, Stefan ^e   Mylius, Veit ^a   Kiefer, Reinhard ^f   Schrank, Bertold ^g   Oertel, Wolfgang H ^a   Dodel, Richard ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b UNIVERSITY OF BONN   (Germany)

^c Klinkum Darmstadt ^*  (Germany)

^d UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^e OTTO VON GUERICKE UNIVERSITY   (Germany)

^f UNIVERSITY OF MÜNSTER   (Germany)

^g DEUTSCHE KLINIK FÜR DIAGNOSTIK   (Germany)

Author keywords

"Bottom up" approach; Costs; Neuromuscular disorders

Indexed keywords

CREATINE; IMMUNOMODULATING AGENT; PYRIDOSTIGMINE; RILUZOLE;

ABSENTEEISM; ADULT; AGE DISTRIBUTION; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; ARTIFICIAL VENTILATION; CAREGIVER BURDEN; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DEMENTIA; DEPRESSION; DISEASE DURATION; DISEASE SEVERITY; DRUG COST; FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY; FEMALE; GERMANY; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; MYASTHENIA GRAVIS; NUTRITIONAL SUPPORT; ONSET AGE; PATIENT CARE; PRIORITY JOURNAL; QUESTIONNAIRE; SEX DIFFERENCE; SOCIOECONOMICS;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; AMYOTROPHIC LATERAL SCLEROSIS; CROSS-SECTIONAL STUDIES; DEMENTIA; FEMALE; GERMANY; HEALTH CARE COSTS; HEALTH EXPENDITURES; HUMANS; INSURANCE, HEALTH; MALE; MIDDLE AGED; MUSCULAR DYSTROPHY, FACIOSCAPULOHUMERAL; MYASTHENIA GRAVIS; SOCIOECONOMIC FACTORS; YOUNG ADULT;

EID: 74849094944     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-009-5256-6     Document Type: Article

References (42)

1. JA Barber SG Thompson 2000 Analysis of cost data in randomized trials: an application of the non-parametric bootstrap Stat Med 19 3219 3236 10.1002/1097-0258(20001215)19:23<3219::AID-SIM623>3.0.CO;2-P 1:STN:280:DC%2BD3M3kt12kuw%3D%3D 11113956
2. Brooks BR (1994) El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on motor neuron diseases/amyotrophic lateral sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial "Clinical limits of amyotrophic lateral sclerosis" workshop contributors. J Neurol Sci 124:96-107
3. J Carpenter J Bithell 2000 Bootstrap confidence intervals: when, which, what? A practical guide for medical statisticians Stat Med 19 1141 1164 10.1002/(SICI)1097-0258(20000515)19:9<1141::AID-SIM479>3.0.CO;2-F 1:STN:280:DC%2BD3c3lvFOiug%3D%3D 10797513 (Pubitemid 30265928)
4. PB Christensen TS Jensen I Tsiropoulos T Sorensen M Kjaer E Hojer-Pedersen MJ Rasmussen E Lehfeldt B de Fine Olivarius 1993 Incidence and prevalence of myasthenia gravis in western Denmark: 1975 to 1989 Neurology 43 1779 1783 1:STN:280:DyaK2c%2FitVejtw%3D%3D 8414031
5. Efron B, Tibshirani RJ (1993) An introduction to the bootstrap. Chapman and Hall, London
6. EJ Emanuel LL Emanuel 1994 The economics of dying. The illusion of cost savings at the end of life N Engl J Med 330 540 544 10.1056/NEJM199402243300806 1:STN:280:DyaK2c7jsVWitQ%3D%3D 8302321 (Pubitemid 24058958)
7. Federal Statistical Office of Germany. http://www.destatis.de. (accessed 15 December 2008)
8. Federal Statistical Office of Germany http://www.destatis.de (accessed 20 May 2009)
9. MF Folstein SE Folstein PR McHugh 1975 "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician J Psychiatr Res 12 3 189 198 10.1016/0022-3956(75)90026-6 1:STN:280: DyaE28%2FntFKjtw%3D%3D 1202204
10. German Diagnosis Related Groups (G-DRG) http://www.g-drg.de (accessed 15 December 2008)
11. Gold MR, Siegel JE, Russell LB, Weinstein MC (1996) Cost-effectiveness in health and medicine. Oxford University Press, New York
12. AM Gray 1998 ALS/MND and the perspective of health economics J Neurol Sci 160 2 5 10.1016/S0022-510X(98)00192-0 (Pubitemid 28522511)
13. HM Hamer A Spottke C Aletsee S Knake J Reis A Strzelczyk WH Oertel F Rosenow R Dodel 2006 Direct and indirect costs of refractory epilepsy in a tertiary epilepsy center in Germany Epilepsia 47 2165 2172 10.1111/j.1528-1167. 2006.00889.x 17201718 (Pubitemid 44952272)
14. AD Hillel RM Miller K Yorkston E McDonald FH Norris N Konikow 1989 Amyotrophic lateral sclerosis severity scale Neuroepidemiology 8 142 150 10.1159/000110176 1:STN:280:DyaL1M3mt1Citg%3D%3D 2725806
15. Institute for Quality and Efficiency in Health Care (IQWIG) Methods for Assessment of the Relation of Benefits to Costs in the German Statutory Health Care System-Version 2.0, http://www.iqwig.de/methods.805.en.html. (accessed 20 May 2009)
16. A Jaretzki RJ Barohn RM Ernstoff HJ Kaminski JC Keesey AS Penn DB Sanders 2000 Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America Neurology 55 16 23 10891897
17. LM Klein DA Forshew 1996 The economic impact of ALS Neurology 47 126 129
18. Kobelt G, Berg J, Atherley D, Hadjimichael O, Joensson B (2004) Costs and quality of life in multiple sclerosis-a Cross-Sectional Study in the USA. SSE/EFI Working Paper Series in Economics and Finance No 594
19. G Kobelt J Berg D Atherly O Hadjimichael 2006 Costs and quality of life in multiple sclerosis: a cross-sectional study in the United States Neurology 66 1696 1702 10.1212/01.wnl.0000218309.01322.5c 16769943 (Pubitemid 43964625)
20. G Kobelt J Berg P Lindgren K Berger WG Elias P Flachenecker M Freidel N Koenig V Limmroth E Straube 2006 Costs and quality of life of multiple sclerosis in Germany Eur J Health Econ 7 34 44 10.1007/s10198-006-0384-8 (Pubitemid 46318953)
21. C Krauth F Hessel T Hansmeier J Wasem R Seitz B Schweikert 2005 Empirical standard costs for health economic evaluation in Germany-a proposal by the working group methods in health economic evaluation Gesundheitswesen 67 736 746 10.1055/s-2005-858698 1:STN:280:DC%2BD2Mrls1Gruw%3D%3D 16235143 (Pubitemid 41604934)
22. JF Kurtzke 1982 Epidemiology of amyotrophic lateral sclerosis Adv Neurol 36 281 302 1:STN:280:DyaL3s%2Fps12jsQ%3D%3D 6983824
23. J Lopez-Bastida L Perestelo-Perez F Monton-Alvarez P Serrano-Aquilar J Luis Alfonso-Sanchez 2008 Social economic costs and health-related quality of life in patients with amyotrophic lateral sclerosis in Spain Amyotroph Later Scler 26 1 7
24. J Lopez-Bastida P Serrano-Aguilar L Perestelo-Perez J Oliva-Moreno 2006 Social-economic costs and quality of life of Alzheimer disease in the Canary Islands, Spain Neurology 67 2186 2191 10.1212/01.wnl.0000249311.80411.93 17190942 (Pubitemid 46035475)
25. PW Lunt PS Harper 1991 Genetic counselling in facioscapulohumeral muscular dystrophy J Med Genet 28 655 664 10.1136/jmg.28.10.655 1:STN:280:DyaK38%2FksF2hsg%3D%3D 1941962
26. D Meltzer M Johannesson 1999 Inconsistencies in the "societal perspective" on costs of the panel on cost-effectiveness in health and medicine Med Decis Making 19 371 377 10.1177/0272989X9901900401 1:STN:280:DyaK1MvkvV2rsA%3D%3D 10520672 (Pubitemid 29474759)
27. AH Moss EA Oppenheimer P Casey PA Cazzolli RP Roos CB Stocking M Siegler 1996 Patients with amyotrophic lateral sclerosis receiving long-term mechanical ventilation. Advance care planning and outcomes Chest 110 249 255 10.1378/chest.110.1.249 1:STN:280:DyaK283osFamuw%3D%3D 8681635
28. D Negrini A Kettle L Sheppard GH Mills DL Edbrooke 2004 The cost of a hospital ward in Europe: is there a methodology available to accurately measure the costs? J Health Org Manag 18 195 206 10.1108/14777260410548437 1:STN:280:DC%2BD2cvlslyrug%3D%3D
29. OECD Purchasing Power Parities (PPPs) for OECD Countries 1980-2007: OECD. 2008. http://www.oecd.org/dataoecd/61/56/39653523.xls (accessed 15 Mai 2008)
30. Official German doctor's fee scale (Einheitlicher Bewertungsmasstab) (2006) Deutscher Aerzteverlag, Koeln
31. RW Orrell R Tawil J Forrester JT Kissel JR Mendell DA Figlewicz 1999 Definitive molecular diagnosis of facioscapulohumeral dystrophy Neurology 52 1822 1826 1:CAS:528:DyaK1MXktVeju7Y%3D 10371529
32. Schöffski O, Graf von der Schulenburg J-M (2007) Health-economic evaluations. (Gesundheitsökonomische Evaluationen.). Springer, Berlin
33. JE Siegel GW Torrance LB Russell BR Luce MC Weinstein MR Gold 1997 Guidelines for pharmacoeconomic studies. Recommendations from the panel on cost effectiveness in health and medicine. Panel on cost Effectiveness in Health and Medicine Pharmacoeconomics 11 159 168 10.2165/00019053-199711020-00005 1:STN:280:DyaK2s3ktVWkuw%3D%3D 10172935
34. AE Spottke M Reuter O Machat B Bornschein S von Campenhausen K Berger R Koehne-Volland J Rieke A Simonow D Brandstaedter U Siebert WH Oertel G Ulm R Dodel 2005 Cost of illness and its predictors for Parkinson's disease in Germany Pharmacoeconomics 23 817 836 10.2165/00019053-200523080-00007 16097843 (Pubitemid 41420428)
35. CA Swinyard GC Deaver L Greenspan 1957 Gradients of functional ability of importance in rehabilitation of patients with progressive muscular and neuromuscular diseases Arch Phys Med Rehabil 38 574 579 1:STN:280: DyaG1c%2Fgt1ahtQ%3D%3D 13459572
36. R Tarricone 2006 Cost-of-illness analysis. What room in health economics? Health Policy 77 51 63 10.1016/j.healthpol.2005.07.016 16139925
37. M Tavakoli M Malek 2001 The cost utility analysis of riluzole for the treatment of amyotrophic lateral sclerosis in the UK J Neurol Sci 191 95 102 10.1016/S0022-510X(01)00618-9 1:STN:280:DC%2BD3Mnkt1OjtQ%3D%3D 11676998 (Pubitemid 33036874)
38. The Federal Ministry for Health and Social Secure http://www.bmg.bund.de
39. The Federation of German Pharmaceutical Industry (2006) Rote Liste. Rote Liste Verlag, Weinheim
40. The German Federal Ministry of Justice http://www.bmj.bund.de (assessed 20 February 2009)
41. I Van Der Steen JP Van Den Berg E Buskens E Lindeman LH Van Den Berg 2009 The costs of amyotrophic lateral sclerosis, according to type of care Amyotroph Lateral Scler May 10 1 27 34 10.1080/17482960802103131
42. Y Winter C Wolfram O Schöffski RC Dodel T Back 2008 Long-term disease-related costs 4 years after stroke or TIA in Germany Nervenarzt 79 918 926 10.1007/s00115-008-2505-3 1:STN:280:DC%2BD1cvpvVygsg%3D%3D 18528673